ArticleJournal of clinical laboratory analysis2026
METTL7B Expression in Sepsis: Association With Disease Severity and 28-Day Mortality.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSepsis is a life-threatening condition associated with high mortality, and current biomarkers remain suboptimal in prognostic evaluation. This study aimed to explore the associations of whole blood methyltransferase-like 7B (METTL7B) expression with disease severity and 28-day mortality in sepsis patients.
methodsIn this prospective cohort study (93 sepsis patients, 22 non-septic ICU controls), whole blood METTL7B (RT-qPCR) and conventional biomarkers (SOFA, PCT, CRP, IL-6) were measured. Dynamic SOFA changes (ΔSOFA from admission to Day 7) were assessed. ROC curves, logistic regression, and a combined model were used.
resultsMETTL7B levels were significantly elevated in sepsis patients compared to non-septic controls (5.6 ± 1.33 vs. 2.44 ± 0.54, p < 0.001), with higher levels observed in non-survivors. Baseline METTL7B levels were significantly higher in patients with a deteriorating SOFA trajectory (ΔSOFA ≥ +2) compared to those with stable or improving courses (p < 0.05). The AUC for METTL7B alone in predicting 28-day mortality was 0.779, outperforming CRP and IL-6. The combination of METTL7B with SOFA and PCT achieved the highest predictive accuracy (AUC = 0.854). Multivariate logistic regression identified METTL7B as associated with disease severity and 28-day mortality risk in patients with sepsis (OR = 1.928, p = 0.017).
conclusionElevated whole blood METTL7B expression is associated with disease severity and unfavorable outcomes in septic patients. When combined with dynamic SOFA and PCT, it improves prognostic stratification. These findings suggest its potential value as a severity-associated complementary marker warranting multi-center validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.